“Dear Doctor”: FDA Advises Firms How To Alert Physicians Of ICD Risks
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers should alert doctors about a newly discovered implantable defibrillator risk before their patients learn about it through the media, FDA recommends in a newly released 1guidance document
You may also be interested in...
Fracture Data Spurs Medtronic To Suspend Sales Of Fidelis ICD Lead
Medtronic's decision to halt worldwide distribution of its Sprint Fidelis defibrillator leads has attracted congressional scrutiny of the company's response to data showing the leads were vulnerable to fracture
Fracture Data Spurs Medtronic To Suspend Sales Of Fidelis ICD Lead
Medtronic's decision to halt worldwide distribution of its Sprint Fidelis defibrillator leads has attracted congressional scrutiny of the company's response to data showing the leads were vulnerable to fracture
When In Doubt: Do Ask, Do Tell FDA About Possible Recalls, Officials Say
Device companies fretting over whether to tell FDA about every product glitch or packaging error that might result in a market withdrawal or recall should phone their FDA district recall officers and ask about it, CDRH Senior Recall Coordinator Michael Verdi said Aug. 14 at an industry conference